Literature DB >> 19320590

Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.

Corinne Vandermeulen1, Frédéric Clement, Mathieu Roelants, Pierre Van Damme, Karel Hoppenbrouwers, Geert Leroux-Roels.   

Abstract

In this observational study, mumps-specific in vitro lymphoproliferation was measured in 24 subjects with low antibody titers and 24 subjects with high antibody titers who received their last vaccine dose up to 16 years previously. Overall, a significant lymphoproliferative response was found in 32 subjects (66.7%)-namely, in 13 (54.2%) of those with low antibody titers and 19 (79.2%) of those with high antibody titers. The mean stimulation index for subjects with low antibody titers was 4.47, whereas that for subjects with high antibody titers was 8.31 (P = .032). Mumps vaccine-induced cell-mediated immunity appears to be more persistent than the antibody response.

Mesh:

Substances:

Year:  2009        PMID: 19320590     DOI: 10.1086/598482

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice.

Authors:  Corinne Vandermeulen; Lieven Verhoye; Sunil Vaidya; Frédéric Clement; Kevin E Brown; Karel Hoppenbrouwers; Geert Leroux-Roels
Journal:  Immunology       Date:  2010-06-25       Impact factor: 7.397

2.  Novel mumps virus epitopes reveal robust cytotoxic T cell responses after natural infection but not after vaccination.

Authors:  Patricia Kaaijk; Maarten E Emmelot; Hugo D Meiring; Cécile A C M van Els; Jelle de Wit
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

3.  Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.

Authors:  L W Ang; F Y Lai; S H Tey; J Cutter; L James; K T Goh
Journal:  Epidemiol Infect       Date:  2012-09-24       Impact factor: 4.434

Review 4.  Knowledge gaps persist and hinder progress in eliminating mumps.

Authors:  R Ramanathan; E A Voigt; R B Kennedy; G A Poland
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 4.169

5.  The resurgence of mumps and pertussis.

Authors:  Martine Sabbe; Corinne Vandermeulen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

6.  The Human CD4+ T Cell Response against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope.

Authors:  Jelle de Wit; Maarten E Emmelot; Martien C M Poelen; Josien Lanfermeijer; Wanda G H Han; Cécile A C M van Els; Patricia Kaaijk
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 7.  Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?

Authors:  Anna R Connell; Jeff Connell; T Ronan Leahy; Jaythoon Hassan
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

8.  Longitudinal Characterization of the Mumps-Specific HLA-A2 Restricted T-Cell Response after Mumps Virus Infection.

Authors:  Josien Lanfermeijer; Marieke M Nühn; Maarten E Emmelot; Martien C M Poelen; Cécile A C M van Els; José A M Borghans; Debbie van Baarle; Patricia Kaaijk; Jelle de Wit
Journal:  Vaccines (Basel)       Date:  2021-12-03

9.  High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.

Authors:  Xiang Sun; Fenyang Tang; Ying Hu; Xiuying Deng; Zhiguo Wang; Minghao Zhou; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

10.  Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks.

Authors:  Gaby Smits; Liesbeth Mollema; Susan Hahné; Hester de Melker; Irina Tcherniaeva; Sandra Waaijenborg; Rob van Binnendijk; Fiona van der Klis; Guy Berbers
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.